Nothing Special   »   [go: up one dir, main page]

MX2019012255A - Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). - Google Patents

Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).

Info

Publication number
MX2019012255A
MX2019012255A MX2019012255A MX2019012255A MX2019012255A MX 2019012255 A MX2019012255 A MX 2019012255A MX 2019012255 A MX2019012255 A MX 2019012255A MX 2019012255 A MX2019012255 A MX 2019012255A MX 2019012255 A MX2019012255 A MX 2019012255A
Authority
MX
Mexico
Prior art keywords
antibody formulation
stable anti
osmr
osmr antibody
approximately
Prior art date
Application number
MX2019012255A
Other languages
English (en)
Inventor
Cornell Manning Mark
Shahrokh Zahra
Nichols Dave
M Levesque Philip
Erik Holcomb Ryan
Original Assignee
Kiniksa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Ltd filed Critical Kiniksa Pharmaceuticals Ltd
Publication of MX2019012255A publication Critical patent/MX2019012255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona, entre otras cosas, formulaciones estables que comprenden un anticuerpo contra el receptor de oncostatina M (OSMR) y que tienen un pH en el intervalo de aproximadamente 6.0 - 7.6, en donde menos de aproximadamente 5 % del anticuerpo contra OSMR existe como especies de alto peso molecular (HMW) en la formulación.
MX2019012255A 2017-04-11 2018-04-11 Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). MX2019012255A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484260P 2017-04-11 2017-04-11
US201762524927P 2017-06-26 2017-06-26
PCT/US2018/027166 WO2018191414A1 (en) 2017-04-11 2018-04-11 Stable anti-osmr antibody formulation

Publications (1)

Publication Number Publication Date
MX2019012255A true MX2019012255A (es) 2019-12-05

Family

ID=62111204

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012255A MX2019012255A (es) 2017-04-11 2018-04-11 Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
MX2023011670A MX2023011670A (es) 2017-04-11 2019-10-11 Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011670A MX2023011670A (es) 2017-04-11 2019-10-11 Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).

Country Status (11)

Country Link
US (4) US10493149B2 (es)
EP (1) EP3609916A1 (es)
JP (2) JP7398958B2 (es)
KR (1) KR20200014738A (es)
CN (2) CN110662761B (es)
AU (1) AU2018251808A1 (es)
BR (1) BR112019021364A2 (es)
CA (1) CA3061705A1 (es)
MA (1) MA53466A (es)
MX (2) MX2019012255A (es)
WO (1) WO2018191414A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3456743T3 (pl) 2013-05-30 2022-03-07 Kiniksa Pharmaceuticals, Ltd. Białka wiążące antygen receptora onkostatyny m
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
CA3121288A1 (en) * 2018-11-29 2020-06-04 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA912136B (en) * 1990-03-29 1992-11-25 Bristol Myers Squibb Co Anti-oncostatin m monoclonal antibodies
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP2019841A2 (en) * 2006-04-21 2009-02-04 Novartis AG Antagonist anti-cd40 antibody pharmaceutical compositions
TWI505838B (zh) * 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
CN107693791B (zh) * 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PL3456743T3 (pl) 2013-05-30 2022-03-07 Kiniksa Pharmaceuticals, Ltd. Białka wiążące antygen receptora onkostatyny m
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US20200283516A1 (en) 2017-03-01 2020-09-10 Medimmune Limited Formulations of monoclonal antibodies

Also Published As

Publication number Publication date
US20180333489A1 (en) 2018-11-22
WO2018191414A1 (en) 2018-10-18
JP2020516651A (ja) 2020-06-11
CN118697867A (zh) 2024-09-27
BR112019021364A2 (pt) 2020-05-05
KR20200014738A (ko) 2020-02-11
US10493149B2 (en) 2019-12-03
JP2023139290A (ja) 2023-10-03
US20190054169A1 (en) 2019-02-21
MA53466A (fr) 2021-09-08
US20200061188A1 (en) 2020-02-27
MX2023011670A (es) 2023-10-18
JP7398958B2 (ja) 2023-12-15
AU2018251808A1 (en) 2019-11-07
CN110662761B (zh) 2024-06-21
US10391170B2 (en) 2019-08-27
CA3061705A1 (en) 2018-10-18
US20220062414A1 (en) 2022-03-03
EP3609916A1 (en) 2020-02-19
US11141479B2 (en) 2021-10-12
CN110662761A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
MX2023011670A (es) Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
EP4385514A3 (en) Formulations
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2018109174A3 (en) Il-11 antibodies
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
PH12020551716A1 (en) Anti-ror antibody constructs
BR112019002371A2 (pt) composições farmacêuticas
WO2018109170A3 (en) Il-11ra antibodies
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MY191581A (en) Anti-pd-1 antibodies
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
CN107397757A8 (zh) 润滑剂制剂
MX2020001885A (es) Formulaciones de daptomicina.
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2020008125A (es) Composiciones que comprenden berberina.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EP3846825A4 (en) FORMULATIONS AND COMPOSITIONS FOR ORTHO-AND/OR RETRO-NASAL ADMINISTRATION AND RELATED SYSTEMS, METHODS AND ITEMS
EP4295903A3 (en) Compositions and methods for treating farber disease
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12020551618A1 (en) Erenumab compositions and uses thereof